Navigation Links
Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
Date:9/25/2007

ectly by individual shareholders or small banks," said James A. Bianco, M.D., President and CEO of CTI. "I'd also like to thank our shareholders who attended the meeting."

During management's presentation, Bianco introduced CTI's strategic platform, which is intended to reduce the risk of current and future cancer drug development. He also reviewed CTI's growth through acquisition initiative, which resulted in the recent acquisition of Systems Medicine and Brostallicin as well as the agreement to acquire Zevalin(R) (ibritumomab tiuxetan) from Biogen IDEC, which is pending closing. Bianco outlined CTI's development plans and upcoming milestones for its pipeline, including XYOTAX(TM) (paclitaxel poliglumex, CT-2103), pixantrone (BBR 2778), and Brostallicin.

"As a result of our recent acquisitions and with our existing pipeline, we have built a powerful, diversified oncology pipeline. This gives us the potential for multiple pivotal and regulatory milestones in 2008 and 2009. We are integrating several components of our strategy, ranging from developing next generation versions of proven effective agents to using cutting edge genomic science to target the right patients for the right drug, which we believe will allow us to manage the risk inherent in cancer drug development," noted Bianco.

"While we anticipate our 2007 net loss to be consistent with the 2006 net loss, we will need to raise additional capital to move our programs forward over the next few years. If we achieve our product pipeline, acquisition, and sales targets, our goal is to break even in 2009 and have a profitable operating company by 2010," Bianco added. For more information on CTI's strategy and development pipeline or to see the archived presentation, please visit our Web site at http://www.cticseattle.com.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to deve
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... 10, 2014 Terascala, the industry leader ... Alan Swahn, a former vice president of product management ... vice president of marketing. Terascala’s software when combined with ... create the highest performance and most reliable solutions for ... guide Terascala’s channel expansion and broaden its product portfolio. ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... for an interview with a researcher, please contact the Communications ... each tip. For more information on ORNL and its research ... Contacts. If you have a general media-related question or comment, ... MATERIALS Moving toward nanorobots . . . ...
... Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced ... (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety ... of Adenovirus Disease Following H em ... T ransplantation [HSCT]).The company also announced that the ...
... Mass., July 12, 2011 Comprendia, leading developer ... the life sciences, sponsored by molecular biology reagents ... an online resource that will support epigenetics research. ... implications for oncology, neurology, metabolism and disease mechanisms. ...
Cached Biology Technology:Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 3Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 4Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 2Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 3Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 4Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 5Comprendia and New England Biolabs Connect Epigenetics Scientists with New Social Media Application 2Comprendia and New England Biolabs Connect Epigenetics Scientists with New Social Media Application 3
(Date:7/10/2014)... -- Fingerprint Cards, (FPC,s) new mobile touch sensor ... Chinese Top 5 smartphone OEM has selected FPC1021 for a ... October 2014.   FPC is proud to announce ... has a planned date for the start of mass production ... phone of 3 million units. The Chinese OEM wants to ...
(Date:7/10/2014)... Sweden , July 8, 2014 ... has won a new design win (DW). An Asian OEM ... date for mass production start in August 2014.   ... Asian smartphone OEM, which has a planned date for start ... an initial ramp order of SEK 5M, for delivery in ...
(Date:7/10/2014)... Ill. , July 9, 2014 ... (EHR), spurred in large part by meaningful use ... health care providers interact with laboratory information. Now, ... in the field of clinical informatics in order ... To address the educational needs of ...
Breaking Biology News(10 mins):FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4
... led by Northwestern Medicine scientists has identified how a defective ... disease known as Giant Axonal Neuropathy, or GAN. The finding ... Investigation . GAN is an extremely rare and ... systems of young children. Those affected show no symptoms at ...
... Health today announced that Vetsulin (porcine insulin zinc suspension), the ... is now available to veterinarians throughout the United States. ... from one in 1001 to one in 500, 2 and ... during the past 30 years.3 Today, along with proper diet ...
... cat, it instinctively avoids the feline or risks becoming dinner. ... the sense of smell, provides evidence that a single gene ... by neurobiologist Thomas Bozza has shown that removing one olfactory ... behavior. The gene, called TAAR4, encodes a receptor that responds ...
Cached Biology News:Rare, lethal childhood disease tracked to protein 2Merck Animal Health announces Vetsulin 2Cat and mouse: A single gene matters 2Cat and mouse: A single gene matters 3
...
... The 500 optimization kit is for fine-tuning ... interest. The kit is recommended when you ... system. The kit includes 0.25 g each ... micrometer diameter gold microcarriers, 100 each of ...
... specifically designed for two-dimensional electrophoresis (2D) ... proteins in this marker have been ... across a 2D gel. The pI ... Mol wt: 17,000-89,000 Physical ...
... can be used to test the crossreactivity ... sera that are commonly used as blocking ... spots for 21 different protein preparations on ... crossreactivity and species specificity, QC of purified ...
Biology Products: